Table 2.
Empirical analysis of factors that may modulate the uptake of IVM in different regions
| Regions | Availability of reproductive care services | Out-of-pocket costs for patients | Incentive for IVM for infertility treatment | Incentive for IVM for onco-fertility preservation |
|---|---|---|---|---|
| Europe | +++ | + |
Low incentive: - Reduced efficiency compared to OS - Utilization of freeze-all strategies in high responders - Limited cost savings for the patient |
High incentive: - Utilization will grow as more centers develop expertise in IVM - Focus on OTO-IVM in spite of experimental nature |
| USA and Canada | +++ | +++ |
Low incentive: - High cost of ART for patients means prioritizing treatments with maximal efficiency |
High incentive: - Utilization will increase as more centers develop expertise in IVM - Focus on OTO-IVM in spite of experimental nature |
| Russia | +++ | ++ |
Low incentive: - Relatively high cost of ART for patients means prioritizing treatments with maximal efficiency |
High incentive: - Utilization will grow as more centers develop expertise in IVM - Focus on OTO-IVM in spite of experimental nature |
| Middle East and Maghreb | ++ | ++ |
High incentive: - High incidence of patients with severe PCOS and underutilized safety measures in high responders - Limited uptake because of lack of experienced centers in the region and perceived complexity of clinical and laboratory IVM procedures |
Low incentive: - Limited availability of onco-fertility programs in the region |
| India | +++ | ++ |
High incentive: - High incidence of patients with severe PCOS and underutilized safety measures in high responders - Limited uptake because of lack of experienced centers in the region and perceived complexity of clinical and laboratory IVM procedures |
High incentive: - Utilization will grow as more centers develop expertise in IVM |
| Southeast Asia | ++ | ++ |
High incentive: - High relative cost of gonadotropins - Increasing uptake in view of emerging number of centers in the region developing a high level of expertise in IVM |
High incentive: - Utilization will grow as more centers develop expertise in IVM - Focus on OTO-IVM in spite of experimental nature |
| China | ++ | ++ |
Low incentive: - High cost of ART for patients means prioritizing treatments with maximal efficiency |
Low incentive: - Limited availability of onco-fertility programs in the region |
| Japan and South Korea | +++ | + |
Low incentive: - Reduced efficiency compared to OS - Utilization of freeze-all strategies in high responders - Limited cost savings for the patient |
High incentive: - Utilization will grow as more centers develop expertise in IVM - Focus on OTO-IVM in spite of experimental nature |
| Australia and New Zealand | +++ | + |
Low incentive: - Reduced efficiency compared to OS - Utilization of freeze-all strategies in high responders - Limited cost savings for the patient |
High incentive: - Utilization will grow as more centers develop expertise in IVM - Focus on OTO-IVM in spite of experimental nature |
| Central and South America | ++ | ++ |
Low incentive: - Lack of experienced centers in the region and perceived complexity of clinical and laboratory IVM procedures |
Low incentive: - Limited availability of onco-fertility programs in the region |
| Middle and Southern Africa | + | ++ |
Low incentive: - Lack of experienced centers in the region and perceived complexity of clinical and laboratory IVM procedures |
Low incentive: - Limited availability of onco-fertility programs in the region |